EUVIMEDEUVIMED entdecken
Open Access

Health and Economic Outcomes of Offering Buprenorphine in Homeless Shelters in Massachusetts

Avik Chatterjee, Emily A Stewart, Sabrina A Assoumou, Stavroula A Chrysanthopoulou, Hana Zwick, Rebecca Arden Harris, Ryan O'Dea, Bruce R Schackman, Laura F White, Benjamin P Linas

JAMA Network Open · 16.10.2024 · 7 (10) · e2437233

DOI: 10.1001/jamanetworkopen.2024.37233 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 16.10.2024. Verfasst von Avik Chatterjee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Grayken Center for Addiction, Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston Me…. Hauptthemen laut MEDLINE: Buprenorphine, Ill-Housed Persons, Opiate Substitution Treatment. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Overdose is the leading cause of death among people experiencing homelessness (PEH), but engagement in medication treatment is low in this population. Shelter-based buprenorphine may be a strategy for increasing initiation and retention on lifesaving medications.

Objective

To estimate clinical outcomes and conduct an economic analysis of statewide shelter-based opioid treatment in Massachusetts. Design, Setting, and Participants This economic evaluation study in Massachusetts used a cohort state-transition simulation model. Two cohorts were modeled starting in 2013, including (1) a closed cohort of a fixed population of PEH with history of high-risk opioid use over their lifetimes and (2) an open cohort in which membership could change over time, allowing assessment of population-level trends over a 10-year period. Data analysis occurred from January 2023 to April 2024. Exposures Model exposures included (1) no shelter-based buprenorphine (status quo) and (2) offering buprenorphine in shelters statewide. Main Outcomes and Measures Outcomes included overdose deaths, quality-adjusted life-years (QALYs) gained, and health care and modified societal perspective costs. Sensitivity analyses were conducted on key parameters.

Results

In the closed cohort analysis of 13 800 PEH (mean [SD] age, 40.4 [13.1] years; 8749 male [63.4%]), shelter-based buprenorphine was associated with an additional 65.4 person-weeks taking buprenorphine over an individual’s lifetime compared with status quo. Shelter-based buprenorphine was cost saving when compared with the status quo, with a discounted lifetime cost savings from the health sector perspective of $1300 per person, and 0.2 additional discounted QALYs per person and 0.9 additional life-years per person. In the population-level simulation, 254 overdose deaths were averted over the 10-year period with the shelter-based buprenorphine strategy compared with the status quo (a 9.2% reduction of overdose deaths among PEH in Massachusetts). Overdose-related and other health care utilization undiscounted costs decreased by $3.0 million and $66.4 million, respectively. Shelter-based opioid treatment generated $44.7 million in additional medication and clinical costs, but saved $69.4 million in overdose and other health costs. Conclusions and Relevance In this economic evaluation of clinical and economic outcomes among PEH, shelter-based buprenorphine was associated with fewer overdose deaths and was cost saving. These findings suggest that broad rollout of shelter-based buprenorphine may be an important tool in addressing the overdose crisis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphineIll-Housed PersonsOpiate Substitution TreatmentHumansMassachusettsMaleFemaleAdultDrug OverdoseMiddle AgedOpioid-Related DisordersQuality-Adjusted Life YearsCost-Benefit AnalysisCohort StudiesOpiate Overdose

Substanzen

Buprenorphine

Autor:innen und Institutionen

  • Grayken Center for Addiction, Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center and Boston University Chobanian & Avedisian School of Med…
  • Section of Infectious Diseases, Department of Medicine, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
  • Department of Biostatistics, Brown University School of Public Health, Providence, R.
  • Department of Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania Penn Presbyterian Medical Center, Philadelphia.
  • Department of Population Health Sciences, Weill Cornell Medicine, New York, New York.
  • Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.

Förderung

  • NIDA NIH HHS

Zitieren

APA

Chatterjee, A., Stewart, E. A., Assoumou, S. A., Chrysanthopoulou, S. A., Zwick, H., Harris, R. A., O'Dea, R., Schackman, B. R., White, L. F., & Linas, B. P. (2024). Health and Economic Outcomes of Offering Buprenorphine in Homeless Shelters in Massachusetts. JAMA Network Open, 7(10), e2437233. https://doi.org/10.1001/jamanetworkopen.2024.37233

Vancouver

Chatterjee A, Stewart EA, Assoumou SA, Chrysanthopoulou SA, Zwick H, Harris RA, et al. Health and Economic Outcomes of Offering Buprenorphine in Homeless Shelters in Massachusetts. JAMA Network Open. 2024;7(10):e2437233. doi:10.1001/jamanetworkopen.2024.37233

BibTeX
@article{Chatterjee2024,
  author = {Chatterjee, Avik and Stewart, Emily A and Assoumou, Sabrina A and Chrysanthopoulou, Stavroula A and Zwick, Hana and Harris, Rebecca Arden and O'Dea, Ryan and Schackman, Bruce R and White, Laura F and Linas, Benjamin P},
  title = {Health and Economic Outcomes of Offering Buprenorphine in Homeless Shelters in Massachusetts},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {10},
  pages = {e2437233},
  doi = {10.1001/jamanetworkopen.2024.37233}
}
Kostenlos starten →